Article
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.
Nature - 1 Jun 2018
Fraietta Joseph A, Nobles Christopher L, Sammons Morgan A, Lundh Stefan, Carty Shannon A, Reich Tyler J, Cogdill Alexandria P, Morrissette Jennifer J D, DeNizio Jamie E, Reddy Shantan, Hwang Young, Gohil Mercy, Kulikovskaya Irina, Nazimuddin Farzana, Gupta Minnal, Chen Fang, Everett John K, Alexander Katherine A, Lin-Shiao Enrique, Gee Marvin H, Liu Xiaojun, Young Regina M, Ambrose David, Wang Yan, Xu Jun, Jordan Martha S, Marcucci Katherine T, Levine Bruce L, Garcia K Christopher, Zhao Yangbing, Kalos Michael, Porter David L, Kohli Rahul M, Lacey Simon F, Berger Shelley L, Bushman Frederic D, June Carl H, Melenhorst J Joseph
Abstract excerpt
Cancer immunotherapy based on genetically redirecting T cells has been used successfully to treat B cell malignancies1-3. In this strategy, the T cell genome is modified by integration of viral vectors or transposons encoding chimaeric antigen receptors (CARs) that direct tumour cell killing. However, this approach is often limited by the extent of expansion and persistence of CAR T cells4,5. Here we report...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.